Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718466 · ClinicalTrials.gov registry record · Phase 3
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
A Phase 3 study of Recurrent or Progressive Glioblastoma, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05718466 is a Phase 3 study of Recurrent or Progressive Glioblastoma that has completed, run by Henry Ford Health System. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05718466, a Phase 3 study of Recurrent or Progressive Glioblastoma, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Chemotherapy
- RADIATION Fractionated radiosurgery
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05718466
The ClinicalTrials.gov registry entry for NCT05718466 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent or Progressive Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05718466 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05718466 about?
NCT05718466 is a clinical study titled "Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy". This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
What is the current status of trial NCT05718466?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2010-11. Estimated completion is 2016-12.
What conditions does trial NCT05718466 study?
This clinical trial studies the following conditions: Recurrent or Progressive Glioblastoma.
What interventions are being tested in trial NCT05718466?
The interventions under investigation include: Bevacizumab (DRUG), Chemotherapy (DRUG), Fractionated radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT05718466?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718466 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.